Skip to content

Evaluation on clinical efficacy of 360-degree trabeculotomy on pigmentary glaucoma

Evaluation on clinical efficacy of 360-degree trabeculotomy on pigmentary glaucoma

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046006
Enrollment
Unknown
Registered
2021-05-02
Start date
2021-10-01
Completion date
Unknown
Last updated
2021-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pigmentary glaucoma

Interventions

treatment group:360-degree trabeculotomy

Sponsors

Beijing Tongren Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for pigmented glaucoma: vertical fusiform pigment particles deposition in the middle and lower part of the posterior cornea, posterior concave iris in the middle periphery, adhesion of pigment particles on the lens and anterior surface of the iris, deposition of pigment particles on the surface of the anterior and posterior capsule and suspensory ligament, inside the eye Pressure> 21mmHg, glaucomatous optic nerve and corresponding glaucomatous visual field damage, gonioscopy: wide angle of the chamber, uniform pigmentation of the trabecular meshwork (Scheie chamber role element classification >= grade II); 2. Aged 18-50 years, the intraocular pressure still cannot be controlled after using the maximum tolerated dose of antiglaucoma drugs; 3. Patients who can understand the risks and complications of surgery and cooperate with surgery; 4. Patients are willing to participate in this research project and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Possess serious underlying diseases of the eye (except pigmented glaucoma) or the whole body; 2. Past eye surgery or laser treatment history; 3. Have a history of other neurological diseases that may affect the visual field; 4. After enrollment, patients who applied to withdraw from this research project for any reason.

Design outcomes

Primary

MeasureTime frame
intraocular pressure;mean defect;

Countries

China

Contacts

Public ContactQing Guoping

Beijing Tongren Hospital

gptsing@126.com+86 15801224486

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026